|
Of standards and armored RNA
January 2011
EDIT CONNECT
SHARING OPTIONS:
AUSTIN, Texas—In early December,
Asuragen Inc. announced
that it had entered into an exclusive
agreement with Novartis to develop
worldwide Armored RNA Quant
(ARQ) BCR-ABL1 RNA International Scale (IS)
Calibrators, as well as laboratory software reporting tools.
According
to Rollie Carlson, Asuragen's president, this
effort is intended to aid laboratories with standardization of BCR-ABL1 RT-qPCR
testing to the
International Scale.
"Our development of the BCR-ABL1 RNA IS Calibrators and
software tool leverages both our
expertise in molecular diagnostics assay
development and our proprietary Armored RNA technology," says Carlson. "We are
pleased to be working with
Novartis in order to develop a standardization of
BCR-ABL1 molecular testing for the entire global testing community."
Under the terms of this agreement, if Asuragen is successful
in the development efforts, it will distribute both the ARQ BCR-ABL1 IS RNA
Calibrators and the software reporting tools to laboratories globally.
Such
distribution will be either directly
from Asuragen or through its distributors
or both, Carlson notes.
The BCR-ABL1 RNA IS Calibrators are intended to
be
compatible with several widely used assays, including both commercially
available and laboratory-developed tests.
In addition to facilitating the standardization of BCR-ABL1
RT-qPCR results to the International Scale, Carlson says the RNA
Calibrators
should "provide unmatched internal and external assay calibration."
The software reporting tool is
expected to help standardize
how BCR-ABL1 RT-qPCR results are reported according to the IS.
Carlson notes that his
company's Armored RNA products in
general serve as excellent controls for molecular diagnostics, which is quickly
becoming a part of routine clinical
laboratory testing.
More big news about Asuragen's BCR/ABL1 testing abilities
came back in mid-July 2010, with
reports that Asuragen and Life Technologies
Corp. achieved
CE-marking and commercial launch in Europe of the BCR/ABL1 Quant
Test, Asuragen's clinically validated and cGMP manufactured test intended to
aid
clinicians in the monitoring and treatment of individuals afflicted with
chronic myeloid leukemia.
Asuragen
manufacturers the monitoring test, which is
exclusively distributed by Life Technologies and runs on the company's Applied
Biosystems CE-marked 7500
Fast Dx Real-Time PCR Instrument.
"The BCR/ABL1 Quant Test provides several advantages over current
methods by
enabling multiplex detection of all targets in a single reaction and
providing unmatched standardization through the use of our proprietary Armored
RNA
Quant technology for external calibrators and process controls," Carlson
says. Code: E011110 Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|